More Articles

Hospira starts phase III programme for biosimilar erythropoietin Biosimilars/News | Posted 13/01/2012

Hospira, self-proclaimed leader in injectable generics, announced on 9 January 2012 that the company had enrolled the first patient in its phase III programme in the US for its biosimilar erythropo...

India at the biotech crossroads Biosimilars/Research | Posted 13/01/2012

‘Indian biotech is at a crossroads. It must not only address the significant health needs of its domestic population, but also position itself to take advantage of the often more profitable global...

UK drug shortages are far from being solved Pharma News | Posted 13/01/2012

Despite attempts to solve problems with shortages of brand-name medicines in the UK, the issue is taking up more of pharmacists’ time, is far from being solved and may be getting worse according to...

First biosimilar G-CSF in Japan Biosimilars/News | Posted 13/01/2012

Mochida Pharmaceuticals (Mochida) and development partner Fuji Pharma announced on 26 December 2011 that they had filed respective applications for the first biosimilar granulocyte colony-stimulati...

Teva gains tentative approval for generic atorvastatin Generics/News | Posted 13/01/2012

Teva announced on 1 December 2011 that it had received tentative approval from FDA for its generic version of Pfizer’s blockbuster cholesterol-reducing medication Lipitor (atorvastatin).

The cost-effectiveness of biosimilars Biosimilars/Research | Posted 16/12/2011

The biotechnology market is growing rapidly, driven by the imminent patent expiry of several major biologicals and enabled by the establishment of regulatory frameworks. The key driver for the bios...

How originator companies delay generic medicines Reports | Posted 16/12/2011

Once a medicine marketed by the originator company is no longer protected by patents or other exclusive rights, generics companies can enter the market with a medicine that is equivalent, in terms...

Samsung makes biosimilars deal with Biogen Idec Biosimilars/News | Posted 16/12/2011

Korean electronics giant Samsung announced on 6 December 2011 that it had entered into a biosimilars joint venture with US biotechnology company Biogen Idec (Biogen).